AXSM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Axsome Therapeutics Inc (AXSM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive analyst sentiment, upcoming FDA approval catalyst for AXS-05, and robust product pipeline make it a compelling investment opportunity. Despite short-term volatility risks, the long-term growth potential outweighs the negatives.
The MACD histogram is positive and expanding, indicating bullish momentum. RSI is neutral at 66.389, and moving averages are converging, suggesting a potential breakout. The price is above the pivot level of 159.016, with resistance at 167.304, indicating strength in the current trend.
Upcoming FDA approval decision for AXS-05 on April 30, which could unlock a $1.6B market opportunity.
Strong revenue growth of 65.03% YoY in Q4
Positive analyst sentiment with multiple price target increases and buy ratings.
High gross margin of 92.89%, indicating strong operational efficiency.
Net income and EPS have declined significantly YoY, reflecting profitability challenges.
Stock has a 40% chance of declining -8.59% over the next month based on historical patterns.
Lack of significant hedge fund or insider trading activity, indicating neutral sentiment from key stakeholders.
In Q4 2025, revenue increased by 65.03% YoY to $195.99M, driven by strong product performance. However, net income dropped by -61.88% YoY to -$28.56M, and EPS declined by -63.64% YoY to -0.56, reflecting ongoing profitability challenges. Gross margin improved to 92.89%, showcasing operational efficiency.
Analysts are overwhelmingly positive on AXSM, with multiple firms raising price targets recently. Guggenheim raised its target to $245, UBS to $251, and RBC Capital to $222, all maintaining buy or outperform ratings. Analysts are optimistic about the AXS-05 approval and the company's growing pipeline, which is expected to drive long-term growth.
